Abstract 315P
Background
First-line durvalumab plus platinum-etoposide significantly improved overall survival without compromising patient-reported outcomes (PROs) in treatment-naïve patients with extensive-stage small cell lung cancer (ES-SCLC) vs control group in the phase III CASPIAN study. The CANTABRICO phase IIIb trial evaluated the safety and effectiveness of durvalumab in combination with platinum-etoposide as a first-line treatment for patients with ES-SCLC in a broader patient population in Spain. Here, we report the PROs to assess the impact of treatment on patients’ quality of life.
Methods
In this study, patients with ES-SCLC received durvalumab plus platinum-etoposide for 4 to 6 cycles as first-line treatment and durvalumab monotherapy as maintenance treatment. PROs were assessed using validated tools, including the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Lung Cancer Module (QLQ-LC13) questionnaires. Assessments were conducted at baseline, during treatment, and at predefined intervals post-treatment. The primary PRO endpoints included changes from baseline in global health status, physical functioning, and lung cancer-specific symptoms. A >10-point score change from baseline was considered clinically relevant/meaningful.
Results
A total of 101 patients were included in the trial. Patients treated with durvalumab plus platinum-etoposide reported clinically meaningful improvements in lung cancer-specific symptoms such as dyspnea and appetite loss compared to baseline. Additionally, cough was also a clinically meaningful improved symptom. These improvements were sustained through most of the treatment period.
Conclusions
The positive PROs observed in the CANTABRICO trial support the use of durvalumab for patients with ES-SCLC in clinical practice, representing a therapeutic option with a clinical impact on patient welfare in the real-world like setting.
Clinical trial identification
NCT04712903.
Legal entity responsible for the study
AstraZeneca Farmacéutica Spain, S.A.
Funding
AstraZeneca Farmacéutica Spain, S.A.
Disclosure
M.D. Isla Casado: Non-Financial Interests, Personal, Invited Speaker: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: AstraZeneca. E. Arriola Aperribay: Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Financial Interests, Personal, Speaker’s Bureau: Lilly, AstraZeneca, Roche, Takeda, MSD, Pfizer, Janssen, BMS; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Roche, Pfizer; Financial Interests, Personal, Advisory Board: Lilly, Sanofi; Financial Interests, Institutional, Other, Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca. M.R. Garcia Campelo: Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, Takeda, Roche/Genentech, MSD Oncology, AstraZeneca; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Roche, AstraZeneca, Pfizer. M.C. Marti Blanco: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Pfizer; Non-Financial Interests, Institutional, Principal Investigator, Local PI: AstraZeneca, Roche. P. Diz Tain: Financial Interests, Personal and Institutional, Invited Speaker: BMS, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Advisory Role: BMS, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Training: BMS, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Principal Investigator: BMS, AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, MSD, Takeda, Pfizer, Amgen; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim, MSD, Takeda; Financial Interests, Personal, Training: Boehringer Ingelheim, MSD, Takeda, Pfizer. L.A. Leon Mateos: Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Bristol Myers Squibb, Merck, MSD, Roche, Sanofi, Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Janssen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Bristol Myers Squibb, Jansen, MSD, Pfizer, Roche, Sanofi, Takeda. M. Majem: Financial Interests, Personal, Advisory Board: Amgen, Roche, AstraZeneca, Takeda, Janssen, Casen Recordati, BMS, Sanofi, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, Roche, AstraZeneca, Pfizer, Takeda, Helsinn, Casen Recordati; Financial Interests, Institutional, Funding: BMS, AstraZeneca, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: Associacio contra el Cancer Barcelona; Non-Financial Interests, Personal, Leadership Role: Asocacion para la Investigacion del Cancer de Pulmon en Mujeres. A. Sanchez Hernandez: Financial Interests, Personal, Speaker’s Bureau: Roche, AstraZeneca, Takeda, Janssen, Amgen, Pfizer; Financial Interests, Personal, Advisory Board: MSD. C. Aguado de la Rosa: Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Sanofi, Takeda; Financial Interests, Personal, Invited Speaker: Novartis, Pfizer, Amgen, Regeneron; Financial Interests, Personal, Expert Testimony: Pierre Fabre, BMS; Financial Interests, Personal and Institutional, Invited Speaker: MSD, Mirati, Amgen, AstraZeneca, Lilly; Other, Personal, Other, Support Attending Meetings/Travels: Roche, Pierre Fabre, MSD, Takeda. B. Massuti Sureda: Non-Financial Interests, Personal, Other, Travel grants: Roche; Financial Interests, Personal, Other, Travel grants: MSD, AstraZeneca; Financial Interests, Personal, Other, Travel grant: Bristol Myers Squibb; Financial Interests, Personal, Other: Takeda, BeiGene. M. Baret, J.L. Lechuga Martos, M. Dominguez: Other, Institutional, Full or part-time Employment: AstraZeneca Farmacéutica Spain. L. Paz-Ares: Financial Interests, Personal, Other, Consulting fees: consultant: Lilly, MSD, Roche, PharmaMar, Merck KGaA (Darmstadt, Germany), AstraZeneca, Novartis, Pfizer, Sanofi, Bayer, BMS, Mirati, GSK, Janssen, Takeda, Regeneron, Gilead, AbbVie, Daiichi Sankyo; Financial Interests, Personal, Other, Grants or contracts: consultant: MSD, AstraZeneca, BMS, Pfizer; Financial Interests, Personal, Other, Honoraria for lectures: AstraZeneca, Janssen, Merck, Mirati, Sanofi. All other authors have declared no conflicts of interest.